Targeting the GAS5–miR-423-3p–SMARCA4 axis presents a novel and promising approach for HCC treatment, potentially improving patient outcomes by disrupting this critical oncogenic pathway. The gene discussed is GAS5; the disease is hepatocellular carcinoma.